BioVector? R4.2 缺陷型小鼠 B 淋巴細胞株 BioVector? R4.2 Mutant Mouse B-Cell Lymphoma Line

第一部分：中文說明

一、 產品基本信息與詳細特征描述

• 產品名稱：BioVector? R4.2 缺陷型小鼠 B 淋巴細胞株

• 細胞株名稱：R4.2

• 物種來源：小鼠 (Mouse, Mus musculus)

• 組織來源：B 細胞淋巴瘤 (B-cell lymphoma) 衍生株

• 細胞屬性：淋巴標本樣細胞 (Lymphoblast-like) / 懸浮生長 (Suspension)

• 生物安全級別：1級 (BSL-1)

• 詳細特征描述：BioVector? R4.2 是一種在免疫學、細胞生物學及抗原提呈機制研究中具有重要地位的特異性突變缺陷型小鼠 B 淋巴細胞株。該細胞系源自經(jīng)化學或物理誘變篩選的 B 細胞淋巴瘤細胞（通常與大名鼎鼎的宿主雜交瘤或淋巴瘤骨架如復合物相關）。R4.2 的核心科學價值在于其特定的基因缺陷表型——通常表現(xiàn)為抗原提呈相關分子（如 MHC II 類分子轉運、加工、或特定的伴侶蛋白如主要組織相容性復合物不變鏈 Ii / CD74）的缺失或嚴重下調。在倒置顯微鏡下，R4.2 細胞呈現(xiàn)出典型的懸浮淋巴母細胞樣形態(tài)，細胞呈圓形、大小較為均一、常以單個細胞或松散的小細胞簇形式在培養(yǎng)基中懸浮生長。由于該細胞株能夠精準阻斷特定抗原的胞內加工或 MHC 分子的表面負載通路，它是國際上用于剖析 B 細胞抗原受體（BCR）信號傳導、胞內轉運內吞動力學、MHC-II 類分子組裝排布以及 T-B 細胞相互作用微觀分子機制的極其珍貴的變異模型。

二、 細胞培養(yǎng)環(huán)境、培養(yǎng)基配方與理化參數(shù)

• 標準培養(yǎng)基配方：

  • 基礎培養(yǎng)基：BioVector? 改良型 RPMI-1640 液體培養(yǎng)基。

  • 血清添加量：10% 至 15% 優(yōu)質滅活胎牛血清 (FBS, Fetal Bovine Serum)。注：針對淋巴類細胞，部分亞株使用經(jīng) 56°C、30分鐘熱滅菌處理的血清能顯著減少補體對懸浮細胞的非特異性損傷。

  • 還原劑（關鍵添加）：添加終濃度為 50 μM (0.05 mM) 的 β-巰基乙醇 (β-mercaptoethanol)。這是維持小鼠淋巴細胞體外活躍分裂和抗氧化損傷的必需成分。

  • 雙抗（可選）：1% 青霉素-鏈霉素溶液（終濃度 100 U/mL 青霉素，100 μg/mL 鏈霉素）。

• 理化與物理培養(yǎng)參數(shù)：

  • 培養(yǎng)溫度：37°C 恒溫培養(yǎng)。

  • 氣體環(huán)境：5% 二氧化碳 ($CO_2$)，飽和空氣濕度環(huán)境。

  • 密度依賴性：懸浮淋巴細胞對細胞密度高度敏感。培養(yǎng)過程中必須維持其細胞密度在 $2 \times 10^5$ 至 $1 \times 10^6$ cells/mL 之間。過低或過高均會導致細胞大量靜息或自發(fā)凋亡。

三、 細胞傳代、復蘇與免疫學實驗標準操作步驟

1. 常規(guī)懸浮傳代操作 (周期 2–3 天)：

   • 懸浮細胞傳代無需胰酶消化。當細胞密度達到約 $1 \times 10^6$ cells/mL 且培養(yǎng)基開始輕微變黃時，啟動傳代。

   • 輕輕搖動培養(yǎng)瓶使細胞分布均勻，吸取全部或部分菌液至無菌離心管中。以每分鐘 800 到 1000 轉 (RPM) 離心 5 分鐘，棄去含代謝廢物的舊培養(yǎng)基。

   • 使用新鮮配制的完全培養(yǎng)基（含 FBS 和 β-巰基乙醇）重懸細胞沉淀。按照 1:3 至 1:5 的稀釋比例分裝至新的培養(yǎng)瓶中，補足培養(yǎng)基體積，置于 37°C 培養(yǎng)箱中繼續(xù)懸浮孵育。

2. 凍存細胞快速復蘇：

   • 從液氮罐中快速取出 R4.2 細胞凍存管，立即投入 37°C 恒溫水浴鍋中劇烈搖動，使其在 1 分鐘左右內完全融化。

   • 用酒精擦拭外壁后，在超凈臺內將細胞懸液轉移至含 5 毫升預熱完全培養(yǎng)基的 15 mL 離心管中，1000 RPM 離心 3 分鐘以徹底去除凍存劑 DMSO。

   • 棄去上清液，加入 5 毫升新鮮完全培養(yǎng)基重懸，接種至 T25 培養(yǎng)瓶中，于 37°C、5% $CO_2$ 培養(yǎng)箱中過夜。次日觀察細胞存活率并計數(shù)。

3. 抗原提呈缺失互補實驗 (Complementation Assay)：

   • 收集對數(shù)生長期的 R4.2 細胞，通過電轉（Electroporation）或慢病毒轉導（Lentiviral Transduction）將缺失的目標野生型基因（如缺失的伴侶蛋白編碼序列）導入 R4.2 細胞中。

   • 篩選獲得穩(wěn)定表達的細胞株后，使用流式細胞術（FACS）檢測表面 MHC-II 類分子表達譜的恢復情況。

   • 將其作為提呈細胞（APC），加入特異性抗原肽段并與對應的 T 細胞雜交瘤共培養(yǎng)，通過測定上清中 IL-2 等細胞因子的分泌，來確證抗原提呈通路的分子修復。

四、 細胞株長期保藏與凍存技術

• 標準凍存液配方：現(xiàn)配現(xiàn)用。55% 改良 RPMI-1640 基礎培養(yǎng)基 + 35% 優(yōu)質胎牛血清 (FBS) + 10% 二甲基亞砜 (DMSO)。

• 冷凍降溫保藏程序：離心收集處于旺盛對數(shù)生長期、活力 $>95\%$ 的 R4.2 細胞。用冷凍保護液輕輕重懸，調節(jié)最終細胞密度為每毫升 $3 \times 10^6$ 到 $8 \times 10^6$ 個細胞。分裝入無菌凍存管中，放入標準程序降溫盒內（確保每分鐘降溫 1°C），置于零下 80°C 超低溫冰箱中過夜。次日必須迅速轉入液氮罐（零下 196°C）中進行永久性氣相或液相保藏。

五、 質量控制標準與科研應用指南

• 質量控制標準：BioVector? 提供的 R4.2 缺陷型小鼠 B 細胞株通過了極為嚴苛的質量控制審查。經(jīng) PCR 及微生物培養(yǎng)檢測確認為 100% 無支原體 (Mycoplasma) 污染，無細菌、真菌及鼠源外源病毒污染；流式細胞術驗證其特定的抗原提呈缺陷相關表面標志物核型完全契合其突變株標準；細胞增殖動力學與懸浮特性保持多世代高度穩(wěn)定。

• 核心實驗應用方向：

  • 抗原加工與提呈機制：用于研究內吞外源抗原在胞內如何降解、加工以及如何被負載到 MHC II 類分子結合槽中的精細分子步驟。

  • 小分子伴侶蛋白功能研究：揭示特定的內質網(wǎng)/高爾基體伴侶蛋白或轉運小泡在免疫細胞內囊泡運輸（Vesicle trafficking）中的生理功能。

  • 免疫受體信號傳導：用于 B 細胞受體（BCR）交聯(lián)后，胞內酪氨酸激酶級聯(lián)活化、鈣離子內流及下游轉錄因子啟動的信號通路剖析。

  • 新型免疫調節(jié)藥物篩查：用于高通量篩查能夠繞過或修復特定抗原提呈缺陷的潛在免疫增強劑、小分子化學靶向藥或抗體藥物。

PART 2: ENGLISH SECTION

I. General Information and Detailed Product Characterization

• Product Name: BioVector? R4.2 Mutant Mouse B-Cell Lymphoma Line

• Cell Line Name: R4.2

• Species Origin: Mouse (Mus musculus)

• Tissue Source: Derived from a mouse B-cell lymphoma mutant lineage.

• Cell Category: Lymphoblast-like / Suspension growth profile

• Biosafety Level: BSL-1

• Detailed Description: BioVector? R4.2 is a highly specialized, mutant-deficient mouse B-cell lymphoma line that occupies a crucial position in examining immunology, intracellular trafficking, and antigen presentation networks. Developed via targeted physical or chemical mutagenesis of an ancestral B-cell lymphoma background, the primary scientific currency of the R4.2 line rests upon its distinct genetic deficiency phenotype. It typically features a disrupted antigen presentation pathway characterized by the lack or severe down-regulation of functional antigen-processing machinery (such as specific molecular chaperones like the invariant chain Ii / CD74, or defects in appropriate MHC Class II intracellular assembly and egress). Under inverted microscopic observation, R4.2 cells exhibit a standard lymphoblast-like suspension morphology, displaying spherical shapes, uniform dimensions, and growing as single cells or loosely aggregated suspension clusters. By offering a precise structural block in specific vesicle routing or MHC loading cascades, R4.2 serves as an invaluable mutant matrix for delineating B-cell receptor (BCR) signal transduction, endocytic kinetic sorting, MHC-II peptide loading complex assembly, and micro-molecular T-B cell cross-talk.

II. Cultivation Environments, Medium Formulations, and Physical Parameters

• Standardized Growth Medium Formulation:

  • Basal Medium: BioVector? Optimized RPMI-1640 Liquid Medium.

  • Serum Supplementation: 10% to 15% premium heat-inactivated Fetal Bovine Serum (FBS). Note: For suspension lymphoid lines, treating serum at 56°C for 30 minutes is highly strategic to neutralize non-specific complement-mediated lysing of fragile cells.

  • Reducing Agent (Critical Supplement): Supplemented with a definitive final concentration of 50 μM (0.05 mM) β-Mercaptoethanol (β-ME). This element is absolutely mandatory to maintain optimal antioxidant defenses and drive continuous proliferation in murine lymphoid cells in vitro.

  • Antibiotics (Optional): 1% Penicillin-Streptomycin Solution (final concentration of 100 U/mL Penicillin and 100 μg/mL Streptomycin).

• Physical Processing Criteria:

  • Incubation Temperature: Constantly maintained at 37°C.

  • Gaseous Atmosphere: 5% Carbon Dioxide ($CO_2$) balanced with ambient air under saturated humidified conditions.

  • Density Dependency Constraints: Highly sensitive to overcrowding and over-dilution alike. The operating cell density must be strictly regulated to span $2 \times 10^5$ to $1 \times 10^6$ cells/mL. Dropping below or exceeding this narrow window triggers immediate mitotic quiescence or widespread accelerated apoptosis.

III. Subculturing, Cryovial Thawing, and Antigen Complementation Protocols

1. Routine Suspension Passaging Schedule (2–3 Day Routine Loop):

   • Suspension lineages do not require enzymatic disassociation (Trypsinization). Initiate subculturing when cell density approaches approximately $1 \times 10^6$ cells/mL and the phenol red indicator in the medium turns slightly yellow.

   • Agitate the culture vessel gently to ensure an even distribution. Transfer the cell suspension into a sterile tube and centrifuge at 800 to 1000 RPM for 5 minutes. Decant the spent supernatant containing metabolic waste.

   • Resuspend the cell pellet cleanly in fresh complete medium enriched with FBS and β-Mercaptoethanol. Dispense back into new culture flasks at a standard subcultivation split ratio spanning 1:3 to 1:5, and return to the 37°C incubator.

2. Cryopreserved Aliquot Thawing:

   • Retrieve an R4.2 cryovial from the liquid nitrogen storage and immediately submerge it into a 37°C water bath, swirling continuously for approximately 1 minute until the contents liquify completely.

   • Sterilize the vial exterior, transfer the cell solution into a sterile conical tube containing 5 mL of pre-warmed complete medium, and spin at 1000 RPM for 3 minutes to pellet cells and eliminate toxic DMSO protectants.

   • Decant the supernatant, resuspend the cells in fresh complete medium, transfer into a T25 flask, and place inside the 37°C, 5% $CO_2$ incubator overnight. Assess viability and execute a cell count the following day.

3. Antigen Presentation Genetic Complementation Assay:

   • Harvest exponential-phase R4.2 cells and introduce the wild-type counterpart of the mutated gene (e.g., the missing chaperone sequence) via electroporation or lentiviral transduction vectors.

   • Post-selection of stable transfectants, utilize Flow Cytometry (FACS) to screen for the functional restoration of surface MHC Class II peptide complexes.

   • Co-culture the engineered R4.2 variants as Antigen Presenting Cells (APCs) alongside responsive T-cell hybridomas in the presence of targeted exogenous protein antigens. Quantify interleukin-2 (IL-2) secretion in the downstream supernatant via ELISA to validate molecular repair of the antigen processing pathway.

IV. Cell Line Cryopreservation and Long-Term Archiving

• Cryoprotective Matrix Formulation: Formulate freshly before use. 55% optimized RPMI-1640 basal medium + 35% premium Fetal Bovine Serum (FBS) + 10% Dimethyl Sulfoxide (DMSO).

• Rate-Controlled Freezing Schedule: Collect R4.2 suspension cells demonstrating high initial viability ($>95\%$). Resuspend the cell mass gently in chilled cryoprotective matrix, targeting a final concentration spanning $3 \times 10^6$ to $8 \times 10^6$ viable cells per milliliter. Aliquot into sterile cryovials. Enclose vials within a standardized container designed to reduce temperature at a predictable 1°C per minute inside a minus 80°C freezer overnight. Transfer the vials into liquid nitrogen storage (-196°C) the next day for indefinite gas-phase preservation.

V. Quality Control Standards and Strategic Research Applications

• Quality Control Standards: Every batch of BioVector? R4.2 cell lines undergoes rigorous validation profiles. PCR screening certifies 100% negative status for Mycoplasma contamination, alongside absolute freedom from adventitious bacterial, fungal, or murine viral pathogens. Flow cytometry confirms that the specific antigen-presentation surface block remains true to the authentic mutant genotype. Proliferation kinetics and suspension behaviors remain steady across extensive passage windows.

• Core Experimental Applications:

  • Antigen Processing Dynamics: Dissecting the precise biochemical steps governing how exogenous proteins are internalized, degraded in endolysosomal vesicles, and loaded into the cleft of MHC Class II molecules.

  • Molecular Chaperone Functional Mapping: Unveiling the precise regulatory role of ER/Golgi chaperones and transport vesicles during intracellular vesicle trafficking within immune subsets.

  • Immune Receptor Cascade Tracking: Profiling downstream tyrosine kinase activation, intracellular calcium flux, and transcription factor nuclear translocation following B-cell receptor (BCR) cross-linking.

  • Immunomodulatory Drug Screening: Serving as an exceptional targeted assay matrix for high-throughput discovery of small molecules, targeted biologics, or chemical enhancers capable of bypassing or correcting specific antigen presentation Blocks.

BioVector NTCC質粒載體菌株細胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址

http://www.nedfriskphoto.com